

Media Release

Straumann and botiss team up to provide complete dental regeneration solutions worldwide

- *Bilateral distribution agreement to be announced at ITI World Symposium*
- *New products and solutions rolled out*
- *Research and clinical experience presented on reduced invasiveness with Roxolid® small implants and on the new Straumann® PURE ceramic implant*

Geneva, 23 April 2014 – At the ITI World Symposium, which opens tomorrow in Geneva, Straumann and botiss are announcing their intention to combine their strengths to provide complete oral tissue regeneration solutions to dental professionals worldwide.

According to an agreement between the two companies, Straumann will have exclusive rights to distribute botiss regenerative system products initially in most Western and Central European countries and the Americas, with co-distribution in Germany. At the same time, botiss will receive rights to distribute Straumann's unique regenerative product Emdogain® in Germany as well as in parts of Eastern Europe and the Middle East. In addition, Straumann has been granted a call option to acquire botiss' shares which, if exercised, could lead to a stake in the German company of up to 30% in 2017.

Based in Berlin, botiss biomaterials is Europe's second largest supplier of oral tissue regeneration products. Its full range of clinically proven, high quality solutions includes membranes for guided tissue and bone regeneration, a full range of bovine, allogenic and synthetic bone graft materials, as well as soft-tissue-graft products. botiss is a fast-growing entrepreneurial company, whose products are used in leading clinics across Europe and are backed by many years of clinical experience. The company prides itself in innovations, such as its maxgraft® bonering for simultaneous implant placement and bone augmentation, as well as the maxgraft® bonebuilder, a bone block customized for individual patients.

Straumann's CEO, Marco Gadola commented: "botiss will enable us to offer an unparalleled range of regenerative solutions to support implant and periodontal procedures. Their quality, effectiveness, handling characteristics and clinical track record will have great appeal to our customers – as will the possibility to obtain every component for a complete solution from one company".

botiss specializes in biomaterials for dental bone and tissue regeneration. Having gained a leading position in Europe, the company is looking to establish itself in other regions. botiss is privately owned and was founded by its two managing partners, Oliver Bielenstein and Dr Dražen Tadić, in 2008.

Dr Tadić noted: "Our products, fields of interest and geographical footprints complement each other perfectly. Straumann's leadership in implant dentistry, its global strength and sales channels will help drive our geographic expansion. The possibilities of brand leverage and of distributing Emdogain are highly attractive and will benefit our partners in Eastern Europe and the Middle East."

The two companies plan to begin distributing the respective products in initial countries in October 2014 and will work together to expedite regulatory clearances in American and Asian markets.

ITI World Symposium provides excellent platform for new research and products

With more than 4000 participants, the ITI World Symposium is the leading academic event in oral implantology. Straumann is benefitting from this year's event in Geneva to announce the roll-out of several innovative products and solutions, in addition to promoting its products through research updates.

Roxidol[®] minimally invasive implants¹ now available throughout Europe

Following initial introductions in selected markets, Straumann's full range of Roxolid implants is now available throughout Europe. This includes the small-diameter and 4mm short implant versions, which reduce invasiveness by avoiding bone augmentation procedures. Presentations in Geneva will refer to two and five year data for the 4mm implant^{2,3} and three-year clinical data on reduced-diameter implants⁴, showing high survival rates and minimal marginal bone loss. Clinicians' observations that short implants can lead to fewer complications, less morbidity, lower costs and more predictable outcomes⁵ will also be discussed. These and other factors make short implants an attractive option, often providing a completely different strategy for implant placement.

Straumann[®] PURE Ceramic Implant officially launched

Straumann's innovative ceramic implant, which was presented at the EAO last October, has completed its controlled market release. Based on the positive feedback and clinical results (97.6% success and survival rates⁶), which will be presented in Geneva, the implant is now generally available to customers in Europe under the brand name Straumann[®] PURE. The implant has exceptional esthetic properties with a translucent ivory color like natural tooth roots. It has a specially-developed ZLA[®] surface to enhance and shorten the healing process and to provide highly predictable osseointegration. Its manufacture involves several innovations including a test procedure to assure the stability of every implant.

New prosthetic components for fixed full-arch restorations

To address the challenging needs of edentulous patients who want reliable, esthetic, full-arch dentures that are fixed, rather than removable, Straumann is introducing a new range of screw-retained implant abutments that offer increased flexibility. In addition to having low profiles, the new abutments are available with 17° and 30° angulations for challenging situations where the posterior implant has to be tilted. Straumann is also preparing the launch of new custom-milled framework components for final fixed prostheses.

Broader CAD/CAM options with efficiency and productivity gains

The Group is also announcing further enhancements to its CAD/CAM system. The latest software release, CARES[®] Visual 8.8, offers further streamlined prosthetic solutions and a broader range of product combinations. The CARES X-Stream[™] workflow, which significantly reduces turnaround time and shipping costs, can now be used for Straumann's Variobase[™] abutment. Numerous restorative options are available for the latter, which offers a highly cost-effective, complete prosthetic solution with an original Straumann connection.

For customers who want CAD/CAM custom prosthetics but do not have the requisite scanning capabilities, Straumann offers a Scan&Shape service, which has also been enhanced with additional functionality.

3M ESPE Trusted Connection

Straumann and 3M ESPE are jointly announcing a 'trusted connection' for the 3M[™] True Definition Scanner. This enables dentists⁷ to obtain original CARES prosthetic solutions for implant- or tooth-borne restorations from just a single intra-oral scan and through a seamless workflow. The trusted connection is a further example of how Straumann is teaming up with leading providers to offer more options, simpler solutions, greater precision and higher productivity to dental professionals. Together with 3M ESPE, Dental Wings and Innovation



MediTech, Straumann offers a completely digital workflow – from digital impression to finished CAM prosthetic – with an excellent level of choice, flexibility and precision

Further details of the aforementioned Straumann solutions are published in the current edition of Starget (www.straumann.com/starget).

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2200 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

E-mail: corporate.communication@straumann.com / investor.relations@straumann.com

Homepage: www.straumann.com

Contacts:

Corporate Communication:

Mark Hill, +41 (0)61 965 13 21

Thomas Konrad, +41 (0)61 965 15 46

Investor Relations:

Fabian Hildbrand, +41 (0)61 965 13 27

Disclaimer

This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

#

¹ Less loss of biological tissues because of smaller implant bed and in case of reduced number of soft and hard tissue augmentation.

² Slotte C, Grønningaeter A, Halmøy AM, Öhrnell LO, Stroh G, Isaksson S, Johansson LÅ, Mordenfeld A, Eklund J, Embring J. Four-millimeter implants supporting fixed partial dental prostheses in the severely resorbed posterior mandible: two-year results. Clin Implant Dent Relat Res. 2012 May;14 Suppl 1:e46-58. Epub 2011 May 20.

³ Slotte C, Grønningaeter A, Halmoy, AM, Ohmell LA, Mordenfeld A, Isaksson S, Johansson LA: Four-millimeter-long posterior-mandible implants: 5-year outcomes of a prospective multicenter study. Clin Implant Dent Realt Res. (submitted)

⁴ Quirynen M, Al-Nawas B, Meijer HJ, Razavi A, Reichert TE, Schimmel M, Storelli S, Romeo E; the Roxolid Study Group. Small-diameter titanium Grade IV and titanium-zirconium implants in edentulous mandibles: three-year results from a double-blind, randomized controlled trial. Clin Oral Implants Res. 2014 Apr 9. [Epub ahead of print]

⁵ Hämmerle C: Interview published in Starget 1/2014. Cochran D: Presentation at the Straumann Corporate Forum, EAO Dublin 2013. Al-Nawas B, Hämmerle C: Presentations at the Straumann Corporate Forum, ITI World Symposium, Geneva 2014.

⁶ Gahlert M, Kniha H, Weingart D, Schild S, Eicholz P, Nickles K, Borman K-H, Prospective Open Label Single Arm Study to Evaluate the Performance of Straumann Ceramic Implants Monotype CIM (Zirconium dioxide) in single tooth gaps in the maxilla and mandible. EAO 2013, Poster 252, Clin. Oral Impl. Res. 24 (Suppl. s9), 2013, p. 123.

⁷ Available initially in US, Iberia and Benelux.